If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
and a million and a half dwellings and over 105 square miles (270 km2) of urban space were destroyed." In Tokyo, Osaka and Nagoya, "the areas leveled (almost 100 square miles (260 km2)) exceeded the areas destroyed in all German cities by both the American and British air forces (about 79 square miles (200 km2))." P-51s also conducted a series of independent ground-attack missions against targets in the home islands. The first of these operations took place on 16 April, when 57 P-51s strafed Kanoya Air Field in Kyushu. In operations conducted between 26 April and 22 June, the American fighter pilots claimed the destruction of 64 Japanese aircraft and damage to another 180 on the ground, as well as a further 10 shot down in flight; these claims were lower than the American planners had expected, however, and the raids were considered unsuccessful. USAAF losses were 11 P-51s to enemy action and seven to other causes. Due to the lack of Japanese air opposition to the American bomber raids, VII Fighter Command was solely tasked with ground-attack missions from July. These raids were frequently made against airfields to destroy aircraft being held in reserve to attack the expected Allied invasion fleet. While the P-51 pilots only occasionally encountered Japanese fighters in the air, the airfields were protected by antiaircraft batteries and barrage balloons. By the end of the war, VII Fighter Command had conducted 51 ground-attack raids, of which 41 were considered successful.
Type I: Properdin levels are unable to be detected Type II: Properdin levels are from 1-10% in comparison to normal levels; function is intact Type III: Properdin levels are normal but the function is absent Evaluations for properdin deficiency may take place in patients with frequenct Neisserial infections with a functioning classical complement pathway (CH50). The AH50 assay is based on the lysis of unsensitized rabbit erythrocytes, however, normal results have been reported in patients with Type I properdin deficiency. Family history of X-linked inheritance should be considered. Further testing includes: Factor D Function by Hemolytic Assay, Properdin Level by ELISA, and gene sequencing to detect mutations for confirmation. Patients with Factor D deficiency or properdin deficiency are advised to receive meningococcal vaccinations and frequent evaluations for meningococcal antibodies. For those with recurring infections, prophylactic antibiotics are administered.
=== Biosimilars === Much of Biocon's current market share includes biosimilars, licensed versions of existing "innovator" products. Biosimilars are eligible for manufacture and sale after the expiration of the original product's patent protection. These are produced under its subsidiary Biocon Biologics. In 2016, it became the first Indian company to launch a biosimilar insulin glargine pen in Japan. In 2017, USFDA approved Mylan-Biocon's biosimilar for the cancer drug Herceptin. In 2018, Biocon and Mylan received the European Commission's approval to market the biosimilar insulin glargine. In 2022 a Biocon subsidiary, Biocon Biologics, bought the biosimilar assets of Viatris for $3.34 billion. In 2021, Biocon and Viatris received approval to launch Semglee, an insulin glargine-yfgn injection, the first interchangble biosimilar for diabetes in the United States. The same year, Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together. Another aspect of the deal involved Bicocon selling 15% of its biologics subsidiary to the Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period. In December 2025, Biocon discontinued its production of the low-cost insulin glargine biosimilar Semglee (insulin glargine-yfgn), causing a significant shortage of basal insulins in the United States as demand moved to other options, in particular Sanofi's Lantus.
== Religion == Most Don Cossacks are Russian Orthodox, who consider themselves guardians of the faith. However, a large percentage of Don Cossacks were Starovers. Even in 1903, a minimum of 150,000 from a total of the 2,500,000 parish members of the Don Eparchy were Starovers. Ataman count Matvei Platov was of a Popovtsy Old Believers Family. Don Cossacks were tolerant of other religions.
Sources: en.wikipedia.org
=== Genetics === The vast majority of people with coeliac disease have one of two types (out of seven) of the HLA-DQ protein. HLA-DQ is part of the MHC class II antigen-presenting receptor (also called the human leukocyte antigen) system and is used by the immune system to distinguish between the body's own cells and others. The two subunits of the HLA-DQ protein are encoded by the HLA-DQA1 and HLA-DQB1 genes, located on the short arm of chromosome 6. There are seven HLA-DQ variants (DQ2 and DQ4–DQ9). Over 95% of people with coeliac disease have the isoform of DQ2 or DQ8, which is inherited in families. The reason these genes increase the risk of coeliac disease is that the receptors formed by these genes bind to gliadin peptides more tightly than other forms of the antigen-presenting receptor. Therefore, these forms of the receptor are more likely to activate T lymphocytes and initiate the autoimmune process. Most people with coeliac bear a two-gene HLA-DQ2 haplotype called DQ2.5. This haplotype is composed of two adjacent gene alleles, DQA1*0501 and DQB1*0201, which encode the two subunits, DQ α5 and DQ β2. In most individuals, this DQ2.5 isoform is encoded by one of two chromosomes 6 inherited from parents (DQ2.5cis). Most coeliacs inherit only one copy of this DQ2.5 haplotype, while some inherit it from both parents; the latter are especially at risk of coeliac disease as well as being more susceptible to severe complications. The frequency of coeliac disease haplotypes can vary by geography.
But creating a type of airplane named AIRPLANE doesn't make you Wilbur Wright." Thomas Haigh, a historian of information technology at the University of Wisconsin–Milwaukee, wrote that "Ayyadurai is, to the best of my knowledge, the only person to have claimed for him or herself the title 'inventor of email'." Haigh argued that while EMAIL was impressive for a teenager's work, it contained no features that were not present on previous electronic mail systems and had no obvious influence on later systems. "The most striking thing about Ayyadurai's claim to have invented electronic mail is how late it comes. Somehow it took him thirty years to alert the world to [his] greatest achievement". Haigh wrote that by 1980, "electronic mail had been in use at MIT for 15 years, Xerox had built a modern, mouse-driven graphical email system for office communication, Compuserve was selling email access to the public, and email had for many years been the most popular application on what was soon to become the Internet." Haigh wrote that Ayyadurai had created "infographic" outlines for his view of history and published the assembled documents under various domain names that he had registered to support his claim. Through his infographics, wrote Haigh, Ayyadurai presented his claims that he "designed and deployed the first version of electronic [mail] system" in 1980, although electronic mail as an executable program was used under the name "Electronic Mail System" before.
E-cigarette makers do not fully disclose information on the chemicals that can be released or synthesized during use. The chemicals in the e-cigarette vapor can be different than with the liquid. Once vaporized, the ingredients in the e-liquid go through chemical reactions that form new compounds not previously found in the liquid. Many chemicals including carbonyl compounds such as formaldehyde, acetaldehyde, acrolein, and glyoxal can inadvertently be produced when the nichrome wire (heating element) that touches the e-liquid is heated and chemically reacted with the liquid. Acrolein and other carbonyls have been found by in e-cigarette vapors that were created by unmodified e-cigarettes, indicating that formation of these compounds could be more common than previously thought. A 2017 review found "Increasing the battery voltage from 3.3 V to 4.8 V doubles the amount of e-liquid vapourized and increases the total aldehyde generation more than threefold, with acrolein emission increasing tenfold." A 2014 study stated that "increasing the voltage from 3.2 to 4.8 V resulted in a 4 to >200 times increase in the formaldehyde, acetaldehyde, and acetone levels". The amount of carbonyl compounds in e-cigarette aerosols varies substantially, not only among different brands but also among different samples of the same products, from 100-fold less than tobacco to nearly equivalent values. The propylene glycol-containing liquids produced the most amounts of carbonyls in e-cigarette aerosols. Propylene glycol could turn into propylene oxide when heated and aerosolized.
Sources: en.wikipedia.org
TMA is isothermal, meaning it is performed at constant temperature. As such, a water bath or heat block can be used instead of a thermal cycler. TMA produces RNA amplicon rather than DNA amplicon. Since RNA is more labile in a laboratory environment, this reduces the possibility of carry-over contamination. TMA produces 100–1000 copies per cycle (PCR and LCR exponentially doubles each cycle). This results in a 10 billion fold increase of DNA (or RNA) copies within about 15–30 minutes.
They perform as high-grade solvents for a broad array of plastics, plasticizers, resins, and lacquers, and are one of the largest classes of synthetic lubricants on the commercial market. Polyesters are important plastics, with monomers linked by ester moieties. Esters of phosphoric acid form the backbone of DNA molecules. Esters of nitric acid, such as nitroglycerin, are known for their explosive properties. There are compounds in which an acidic hydrogen of acids mentioned in this article are not replaced by an organyl, but by some other group. According to some authors, those compounds are esters as well, especially when the first carbon atom of the organyl group replacing acidic hydrogen, is replaced by another atom from the group 14 elements (Si, Ge, Sn, Pb); for example, according to them, trimethylsilyl acetate CH3COOSi(CH3)3 is a trimethylsilyl ester of acetic acid, and dibutyltin dilaurate (CH3(CH2)10COO)2Sn((CH2)3CH3)2 is a dibutylstannylene ester of lauric acid, and the Phillips catalyst CrO2(OSi(OCH3)3)2 is a trimethoxysilyl ester of chromic acid (H2CrO4).
== Function == Natural articular cartilage is an inhomogeneous, anisotropic, and viscoelastic tissue. The structure, described above 1.1.2. allows the cartilaginous tissue to have superior mechanical properties in order to perform the functions necessary. Synthetic cartilage will attempt to mimic the functional properties of natural cartilage, which can be broken down into two main aspects.
== Bone remodeling == Bone is a dynamic tissue that is constantly being reshaped by osteoblasts, which produce and secrete matrix proteins and transport mineral into the matrix, and osteoclasts, which break down the tissues.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.